Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial-Reference-Cited by-同舟云学术

Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial

Published:2021-06-16 Issue:4 Volume:8 Page:2603-2607
ISSN:2055-5822
Container-title:ESC Heart Failure
language:en
Short-container-title:ESC Heart Failure

Author:

Verma Subodh¹,Leiter Lawrence A.²,Zinman Bernard³,Sharma Abhinav⁴,Mattheus Michaela⁵,Fitchett David⁶,George Jyothis⁷,Ofstad Anne Pernille⁸,Kosiborod Mikhail N.⁹,Wanner Christoph¹⁰,Inzucchi Silvio E.¹¹

Affiliation:

1. Division of Cardiac Surgery St. Michael's Hospital, University of Toronto Toronto ON Canada

2. Li Ka Shing Knowledge Institute St. Michael's Hospital, University of Toronto Toronto ON Canada

3. Lunenfeld‐Tanenbaum Research Institute Mount Sinai Hospital, University of Toronto Toronto ON Canada

4. McGill University Health Centre, McGill University Montreal QC Canada

5. Boehringer Ingelheim Pharma GmbH & Co. KG Ingelheim Germany

6. Division of Cardiology St. Michael's Hospital, University of Toronto Toronto ON Canada

7. Boehringer Ingelheim International GmbH Ingelheim Germany

8. Boehringer Ingelheim Norway KS Asker Norway

9. Saint Luke's Mid America Heart Institute University of Missouri—Kansas City Kansas City MO USA

10. Würzburg University Clinic Würzburg Germany

11. Yale University School of Medicine New Haven CT USA

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ehf2.13374

Reference18 articles.

1. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

2. Association of Cardiometabolic Multimorbidity With Mortality

3. Intensive blood pressure lowering in patients with and patients without type 2 diabetes: a pooled analysis from two randomized trials;Brouwer TF;Diabetes Care,2018

4. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

5. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Case-Based Implementation of Heart Failure Therapies, A Consensus Pathway by The Saudi Heart Failure Working Group;Journal of the Saudi Heart Association;2024-06-01

2. Understanding the Association of Tropical SST Anomalies on the ISMR During Extreme IOD Events;Pure and Applied Geophysics;2023-12-17

3. Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial;Diabetes, Obesity and Metabolism;2023-10-26

4. mTORC1 and SGLT2 Inhibitors—A Therapeutic Perspective for Diabetic Cardiomyopathy;International Journal of Molecular Sciences;2023-10-11

5. Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia;Cardiovascular Diabetology;2023-08-31